SCHEMBL758324

SCHEMBL758324

Nc1ncncc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 2/20 0.48
KDM4E B2RXH2 5/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM6B O15054 1/20 0.44
KDM4A O75164 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
KDM4D Q6B0I6 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HCAR2 Q8TDS4 2/20 0.43
GABRP O00591 5/20 0.41
GABRD O14764 5/20 0.41
GABRA1 P14867 5/20 0.41
GABRB1 P18505 5/20 0.41
GABRG2 P18507 5/20 0.41
GABRB3 P28472 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4717959 0.98 NAPRT (0.47) NAPRTKDM4EKMT2AMEN1ALDH1A1
SCHEMBL3663171 0.83 SIRT3 (0.42) NAPRTKMT2AMEN1TDP1CYP1A2
SCHEMBL31139857 0.81 NTRK1 (0.39) NAPRTKMT2AMEN1TDP1HCAR2
SCHEMBL23094464 0.81 NTRK1 (0.39) NAPRTKMT2AMEN1TDP1HCAR2
SCHEMBL68960 0.80 KDM4E (0.47) NAPRTKDM4EKMT2AMEN1ALDH1A1
SCHEMBL30858777 0.78 P2RX7 (0.46) KDM4EALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL3046078 0.76 KDM4E (0.50) KDM4EALDH1A1MAPTL3MBTL1LMNA
SCHEMBL1230875 0.76 NTRK1 (0.44) NTRK1PIK3CDIKBKETBK1
SCHEMBL2575802 0.76 HCAR2 (0.44) NAPRTKDM4EKMT2AMEN1ALDH1A1
SCHEMBL9632777 0.75 HCAR2 (0.40) NAPRTKDM4EKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119552597-A Preparation method of high-performance composite binder for graphite negative electrode 江阴纳力新材料科技有限公司 2025-03-04 CN claimed
CN-113200924-B 4-amino-5-pyrimidine formamide compound and preparation method and application thereof 南开大学 2022-11-01 CN claimed
CN-113200924-A 4-amino-5-pyrimidine formamide compound and preparation method and application thereof 南开大学 2021-08-03 CN claimed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
JP-5112559-A None JP disclosed
JP-9077766-A None JP disclosed
CN-119552597-A Preparation method of high-performance composite binder for graphite negative electrode 江阴纳力新材料科技有限公司 2025-03-04 CN disclosed
WO-2024255845-A1 PROTEIN DEGRADATION AGENT, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 中国科学院上海药物研究所 2024-12-19 WO disclosed
CN-119143748-A Protein degradation agent, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2024-12-17 CN disclosed
US-11702401-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2023-07-18 US disclosed
US-11702401-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2023-07-18 US disclosed
US-11702401-B2 Compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2023-07-18 US disclosed
WO-1996013262-A1 MUSCARINE ANTAGONISTS MERCK & CO., INC. (US) 1996-05-09 WO disclosed
JP-H05112559-A 4-AMINO-5-PYRIMIDINECARBOXYLIC ACID DERIVATIVE MORISHITA ROUSSEL KK 1993-05-07 JP disclosed
US-5089490-A Cephem derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1992-02-18 US disclosed
US-4758556-A Cephem derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1988-07-19 US disclosed
US-4550168-A Benzisoselenazolones and a process for the treatment of inflammatory diseases A. NATTERMANN & CIE GMBH (DE) 1985-10-29 US disclosed
EP-0100899-A2 Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them A. Nattermann & Cie. GmbH (DE) 1984-02-22 EP disclosed
US-4399131-A Cephem derivatives HOECHST AG (DE) 1983-08-16 US disclosed
US-4278793-A ANTIBIOTICS, BACTERICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1981-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702401-B2 Compounds and methods of use TGFB2, TGFB1, HDGF NAPRT 2209/4885KDM4E 1713/4885KMT2A 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.